Facebook
Twitter
LinkedIn
Forward
Ace the Case Challenge Series: The Intersection of MASH and Cardiometabolic Risk
This Ace the Case Series is designed to be quick and offer high-level takeaways and pearls.
Case #1: A 37-Year-Old Man with Incidental Hepatic Steatosis on Abdominal Ultrasound
During this Ace the Case activity, you will learn about risk factors for metabolic dysfunction–associated steatotic liver disease (MASLD), metabolic dysfunction–associated steatohepatitis (MASH), and advanced fibrosis, as well as the current and emerging noninvasive liver assessment tests.
Case #2: A 60-Year-Old Type 2 Diabetic Woman with MASH and F3 Liver Fibrosis
This Ace the Case activity will review a detailed case discussion on the latest clinical care guidelines and emerging treatments for MASH. Participants will explore novel treatment targets and the most recent clinical data for treating patients with MASH and cardiometabolic comorbidities. Gain practical insights for individualizing patient care plans in your practice. Don’t miss this opportunity to enhance your expertise and improve patient outcomes
Target Audience
The educational design of this activity addresses the needs of US-based healthcare professionals, including cardiologists, endocrinologists, lipidologists, primary care clinicians (PCPs), registered nurses, advanced practice registered nurses, dieticians, pharmacists, and other allied health professionals involved in the management and treatment of cardiometabolic patients.
Learning Objectives
After completing this activity, the participant should be better able to:
- Explain MAFLD/MASH pathogenesis and the role that cardiovascular and cardiometabolic risk factors, including obesity and diabetes, play in MASH progression in order to improve the identification of MASH.
- Describe current and emerging approaches and tools to screen and diagnose MAFLD and MASH in clinical practice.
- Review the efficacy and safety of current treatments for MAFLD and MASH, including the role of GLP-1 Ras.
- List emerging MASH pharmacotherapies that aim to target various metabolic, inflammatory, and fibrotic pathways involved in disease progression.
- Develop individualized treatment regimens for patients with MAFLD or MASH based on current treatment options and updated guidelines and consensus statements.
Amreen Dinani, MD, FRCPC, ABOM
Associate Professor of Medicine
Duke University Health
Durham, NC
Jennifer Green, MD
Professor of Medicine, Division of Endocrinology
Duke Clinical Research Institute
Duke University School of Medicine
Durham, NC
All CME information can be found within each case. Once you enroll into this series, please visit the last tab of this page "Take Course" to select and start a patient Ace the Case activity.
Available Credit
- 0.50 ACPE Pharmacy
- 0.50 AMA PRA Category 1 Credit™
- 0.50 ANCC
- 0.50 CDE
- 0.50 Participation